Total Payments
$19,615
2024 Payments
$2,199
Companies
4
Transactions
18
Payment Breakdown by Category
Research$19,118 (97.5%)
Food & Beverage$320.08 (1.6%)
Travel$176.27 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,118 | 9 | 97.5% |
| Food and Beverage | $320.08 | 8 | 1.6% |
| Travel and Lodging | $176.27 | 1 | 0.9% |
Payments by Type
Research
$19,118
9 transactions
General
$496.35
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $16,377 | 6 | $0 (2023) |
| Eli Lilly and Company | $2,741 | 3 | $0 (2024) |
| LivaNova USA, Inc. | $335.22 | 2 | $0 (2022) |
| UCB, Inc. | $161.13 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,199 | 3 | Eli Lilly and Company ($2,144) |
| 2023 | $16,466 | 10 | PFIZER INC. ($16,377) |
| 2022 | $949.90 | 5 | Eli Lilly and Company ($597.00) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,144.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | ||||||
| 09/09/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: Neurology | ||||||
| 04/08/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Neurology | ||||||
| 12/07/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $928.85 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $928.85 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/11/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Neurology | ||||||
| 08/17/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $8,858.45 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 07/18/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Immunology | ||||||
| 05/18/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $748.85 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 04/13/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,912.39 | Research |
| Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 02/27/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Immunology | ||||||
| 01/03/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $30.87 | General |
| Category: Immunology | ||||||
| 10/10/2022 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Neurology | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $297.00 | Research |
| Study: PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | ||||||
| 03/04/2022 | LivaNova USA, Inc. | VNS Therapy (Device) | Travel and Lodging | In-kind items and services | $176.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/04/2022 | LivaNova USA, Inc. | VNS Therapy (Device) | Food and Beverage | In-kind items and services | $158.95 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $16,377 | 6 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | Eli Lilly and Company | $2,144 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | Eli Lilly and Company | $300.00 | 1 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $297.00 | 1 |
About Dr. Sharoon Qaiser, M.D
Dr. Sharoon Qaiser, M.D is a Neurology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2014. The National Provider Identifier (NPI) number assigned to this provider is 1881003978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sharoon Qaiser, M.D has received a total of $19,615 in payments from pharmaceutical and medical device companies, with $2,199 received in 2024. These payments were reported across 18 transactions from 4 companies. The most common payment nature is "" ($19,118).
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology with Special Qualifications in Child Neurology
- Location Lexington, KY
- Active Since 08/04/2014
- Last Updated 05/02/2022
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1881003978
Products in Payments
- NURTEC ODT (Drug) $16,377
- VNS Therapy (Device) $335.22
- Briviact (Drug) $74.70
- Cimzia (Drug) $68.75
- Fintepla (Drug) $17.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Lexington
Dr. Nicole Everman, M.d, M.D
Neurology — Payments: $506,986
Neurology $506,986
Toufic Fakhoury, Md, MD
Neurology — Payments: $393,864
Neurology $393,864
Larry Goldstein, Md, MD
Neurology — Payments: $28,134
Neurology $28,134
Jagannadha Avasarala, Md, Phd, MD, PHD
Neurology — Payments: $26,770
Neurology $26,770
Fred Odago, Md, MD
Neurology — Payments: $22,752
Neurology $22,752
John Slevin, Md, MD
Neurology — Payments: $16,946
Neurology $16,946